Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Biliary Tract Cancer”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Testing effectiveness (Phase 2)Study completedNCT04722133
What this trial is testing

Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy

Who this might be right for
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
Yonsei University 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05985707
What this trial is testing

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

Who this might be right for
HER2-positive Colorectal CancerHER2-positive Biliary Tract Cancer
Peking University Cancer Hospital & Institute 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT04430738
What this trial is testing

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Who this might be right for
Colorectal CarcinomaGastric AdenocarcinomaGEJ Adenocarcinoma+3 more
Seagen, a wholly owned subsidiary of Pfizer 40
Early research (Phase 1)Ended earlyNCT05194072
What this trial is testing

Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Who this might be right for
Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms+8 more
Seagen, a wholly owned subsidiary of Pfizer 250
Testing effectiveness (Phase 2)Ended earlyNCT00478140
What this trial is testing

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

Who this might be right for
Adenocarcinoma of the Extrahepatic Bile DuctAdenocarcinoma of the GallbladderMalignant Neoplasm+4 more
National Cancer Institute (NCI) 4
Testing effectiveness (Phase 2)UnknownNCT05417230
What this trial is testing

RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2

Who this might be right for
Biliary Tract Cancer
Jiangsu Cancer Institute & Hospital 29
Early research (Phase 1)UnknownNCT02662348
What this trial is testing

T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System

Who this might be right for
Esophageal CancerGastric CancerPancreatic Cancer+3 more
Yi Miao 6
Testing effectiveness (Phase 2)Looking for participantsNCT05523947
What this trial is testing

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

Who this might be right for
HER2-Positive Solid Tumor
Yuhan Corporation 137
Testing effectiveness (Phase 2)UnknownNCT04837508
What this trial is testing

MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Who this might be right for
Advanced or Metastatic Biliary Tract Cancer
Shanghai Miracogen Inc. 86
Testing effectiveness (Phase 2)Looking for participantsNCT06434597
What this trial is testing

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Who this might be right for
Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
Shanghai Pharmaceuticals Holding Co., Ltd 60
Not applicableLooking for participantsNCT07124000
What this trial is testing

DESTINY-PANTUMOUR04

Who this might be right for
Adenocarcinoma (NOS)Anal CancerBladder Cancer+24 more
AstraZeneca 100
Testing effectiveness (Phase 2)Looking for participantsNCT05969860
What this trial is testing

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Who this might be right for
Advanced Anal CarcinomaAdvanced Biliary Tract CarcinomaAdvanced Bladder Carcinoma+40 more
Mayo Clinic 200
Testing effectiveness (Phase 2)Looking for participantsNCT05150691
What this trial is testing

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumor
DualityBio Inc. 796
Testing effectiveness (Phase 2)Looking for participantsNCT06431490
What this trial is testing

TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 103
Early research (Phase 1)UnknownNCT04460456
What this trial is testing

SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Who this might be right for
HER2 Positive Solid Tumors
Silverback Therapeutics 58
Large-scale testing (Phase 3)Looking for participantsNCT06282575
What this trial is testing

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer
Jazz Pharmaceuticals 286
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07159217
What this trial is testing

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Who this might be right for
Biliary Tract CancerDisitamab VedotinLenvatinib+1 more
Peking Union Medical College Hospital 65
Not applicableNo Longer AvailableNCT04578444
What this trial is testing

An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

Who this might be right for
HER2-Positive Advanced Biliary Tract Cancer
Jazz Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT04278144
What this trial is testing

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal Cancer+2 more
Bolt Biotherapeutics, Inc. 175
Early research (Phase 1)Ended earlyNCT04209465
What this trial is testing

BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Who this might be right for
Solid Tumor
Black Diamond Therapeutics, Inc. 91
Load More Results